Glaxosmithkline Pharmaceuticals Ltd Share Price Today - Glaxosmithkline Pharmaceuticals Ltd Stock Price Live NSE/BSE

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO BSE: 500660

₹2336.40

(-1.28%)

Sat, 09 May 2026, 04:25 pm

MTF 5xInvest in Glaxosmithkline Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap401.66B

PE Ratio38.77

Dividend1.77

24.5K

Glaxosmithkline Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
42092.32
Net Profit
927.58
P/B
24.98
Sector P/E
34.14
P/E
52.54
EV/EBITDA
35.66
Debt/Equity (Industry)
0.08
Interest Cover (Industry)
42.77
ROCE (Industry)
23.88
RONW (Industry)
19.04
ROE
49.75
ROCE
59.29
Debt/Equity
0.01
EPS (TTM)
59.37
Dividend Yield
2.17
Book Value
100.80
Interest Cover
962.74

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends after 3 years are expected to be covered by earnings (1.5x coverage).
GlaxoSmithKline Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
GlaxoSmithKline Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
GlaxoSmithKline Pharmaceuticals's earnings growth is expected to exceed the India market average.

Cons

Dividends paid are not well covered by earnings (0.3x coverage).
Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
GlaxoSmithKline Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for GlaxoSmithKline Pharmaceuticals is expected to increase but not above the 50% threshold in 2 years time.
GlaxoSmithKline Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	75	75	75	75	75
FII	4.62	4.64	4.79	4.88	4.52
DII	7.68	7.70	7.75	7.70	7.79
Public	12.70	12.66	12.45	12.41	12.69
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

58.22

MACD

5.62

50 DMA

2433.65

200 DMA

2597.40

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	2912.07	2644.07	2490.23	2376.07	2222.23	2108.07	1840.07
Fibonacci	2644.07	2541.69	2478.44	2376.07	2273.69	2210.44	2108.07
Camarilla	2410.10	2385.53	2360.97	2376.07	2311.83	2287.27	2262.70

Pivots Level: Classic

+536

2912.07

+268

2644.07

+114.17

2490.23

2376.07

Pivot Point

LTP: 2476.90

-153.83

2222.23

-268

2108.07

-536

1840.07

Moving Average

SMAEMA

Period

Value

10-EMA
2423.28
20-EMA
2414.99
30-EMA
2416.00
50-EMA
2427.37
100-EMA
2472.94
200-EMA
2547.91

Announcement Date	Purpose	Action	Ex Date
09 Feb 2026	board-meetings	Quarterly Results
06 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
13 May 2025	dividend	₹42.00 Dividend /Share	30 May 2025
13 May 2025	agm
30 Apr 2025	dividend	Final Dividend - Rs. - 42	30 May 2025
29 Oct 2024	dividend	₹12.00 Dividend /Share	07 Nov 2024
07 Oct 2024	dividend	Interim Dividend - Rs. - 12	07 Nov 2024
17 May 2024	dividend	₹32.00 Dividend /Share	31 May 2024
17 May 2024	agm
01 May 2024	dividend	Final Dividend - Rs. - 32	31 May 2024

Glaxosmithkline Pharmaceuticals Ltd

Cipla Ltd

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Glaxosmithkline Pharmaceuticals Ltd About

GlaxoSmithKline Pharmaceuticals is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

Industry

Pharmaceuticals - Multinational

Founded

1924

Headquarters

CEO

Renu S Karnad

Employees

Contact

Website

http://www.gsk-india.com

askus@gsk.com; ajay.a.nadkarni@gsk.com

Phone

91-022-24959595

Location

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Year	History
2019	Won Brand of the Year award in acute category at 6th AWACS Awards. Won Best Sales and Operations Planning Practice in Pharma award. Recognised as Best Workplaces for Women by Great Places to Work India.
2020	Recognised as one of 100 Best Companies for Women in India by Working Mother and AVTAR. Conferred Fair Business Practices award (2019-20) by Council for Fair Business Practices. Recognised as Silver employer under India Workplace Equality Index.
2021	Recognised as one of India's Best Workplaces in Health & Wellness by Great Place to Work. Conferred CNBC TV18 India Risk Management Award in Pharma sector.
2022	Launched once-daily single inhaler-triple therapy for COPD patients. Teamed up with MS Dhoni for 6-in-1 vaccination awareness campaign.
2024	Reported strong double-digit growth and improved profitability for the quarter.

Client Name	Order Side	QTY	Avg Price	Date
T ROWE PRICE INTERNATIONAL INC	Sell	1087076	1207	18 May 2007
HSBC INVESTMENTS HONG KONG LIMITED	Buy	1047076	1207	18 May 2007

Glaxosmithkline Pharmaceuticals Ltd News

GSK Pharma Schedules Investor Meet on May 13, 2026

GlaxoSmithKline Pharmaceuticals has announced a digital group analyst and institutional investor meeting on May 13, 2026, under SEBI Listing Regulations.

08 May 2026

companies

GSK Pharma Schedules Investor Meet on May 13, 2026

GlaxoSmithKline Pharmaceuticals has announced a digital group analyst and institutional investor meeting on May 13, 2026, under SEBI Listing Regulations.

07 May 2026

companies

GSK Pharma Board Meet on May 13 for FY26 Results

GlaxoSmithKline Pharmaceuticals Limited announces board meeting on May 13, 2026, to approve audited financial results for year ended March 31, 2026, and consider dividend recommendation.

22 Apr 2026

companies

GSK Appoints Vinay Subramanian as Commercial Head

GlaxoSmithKline Pharmaceuticals Limited announces the appointment of Mr. Vinay Subramanian as Commercial Head – Oncology to its leadership team, effective 20th April 2026, bringing over 24 years of pharmaceutical industry experience.

22 Apr 2026

companies

GSK Pharma discloses authorized personnel for materiality assessment

GlaxoSmithKline Pharmaceuticals Limited has disclosed four authorized personnel including Managing Director Bhushan Akshikar and CFO Ronojit Biswas for determining materiality of events under SEBI Regulation 30(5). The disclosure was made to BSE and NSE on 21 April 2026.

22 Apr 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800